Literature DB >> 26086765

Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms.

Vishal Mehta1, Colin D Ferrie, J Helen Cross, Gayatri Vadlamani.   

Abstract

BACKGROUND: This is an updated version of the original Cochrane review published in Issue 1, 2007.Epilepsy is a disorder with recurrent epileptic seizures. Corticosteroids have been used in the treatment of children with epilepsy and have significant adverse effects. Their efficacy and tolerability have not been clearly established.
OBJECTIVES: To determine the efficacy, in terms of seizure control, improvements in cognition and in quality of life and tolerability of steroids compared to placebo or other antiepileptic drugs in children with epilepsy, excluding epileptic spasms. SEARCH
METHODS: We searched the following databases: The Cochrane Epilepsy Group Specialized Register (1 August 2014); CENTRAL, (The Cochrane Library Issue 7, July 2014); MEDLINE (1946 to 1 August 2014); EMBASE (1966 to December 2004); Database of Abstracts of Reviews of Effectiveness (DARE; Issue 3 of the database published in The Cochrane Library Issue 7, July 2014); ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform ICTRP (1 August 2014).We checked the reference lists of retrieved studies for additional reports of relevant studies. SELECTION CRITERIA: All randomised controlled trials of administration of corticosteroids to children (less than 16 years) with epilepsy. DATA COLLECTION AND ANALYSIS: For this update two review authors independently selected trials for inclusion and extracted data. Outcomes included cessation of seizures, reduction in seizure frequency, improvement in cognition, quality of life and adverse effects of steroids. MAIN
RESULTS: A single RCT was included that recruited five children in a double blind cross-over trial. One child was withdrawn prematurely from the study and another had infantile spasms and hence was excluded from further analysis. Adrenocorticotrophin hormone (ACTH 4-9) was administered. Of the three children analysed, one showed a reduction in seizures of 25% to 50% at both the low and higher doses of corticosteroids compared to placebo; one child showed a reduction in seizures at the higher dose only and one child showed no reduction in seizures at either dose. No adverse effects were reported. AUTHORS'
CONCLUSIONS: Since the last version of this review no new evidence has been found for the efficacy of corticosteroids in treating childhood epilepsies. Clinicians using steroids in childhood epilepsies, other than for epileptic spasms, should take this into account before using these agents.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26086765      PMCID: PMC7390481          DOI: 10.1002/14651858.CD005222.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  36 in total

1.  Management of epilepsy.

Authors:  T Deonna
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

2.  Brain shrinkage and subdural effusion associated with ACTH administration.

Authors:  J Satoh; H Takeshige; H Hara; Y Fukuyama
Journal:  Brain Dev       Date:  1982       Impact factor: 1.961

3.  Short-course of prednisolone in solitary cysticercus granuloma: a randomized, double-blind, placebo-controlled trial.

Authors:  Monika Singla; Sudesh Prabhakar; Manish Modi; Bikash Medhi; Niranjan Khandelwal; Vivek Lal
Journal:  Epilepsia       Date:  2011-07-21       Impact factor: 5.864

4.  Landau-Kleffner syndrome: a pharmacologic study of five cases.

Authors:  C Marescaux; E Hirsch; S Finck; P Maquet; E Schlumberger; F Sellal; M N Metz-Lutz; Y Alembik; E Salmon; G Franck
Journal:  Epilepsia       Date:  1990 Nov-Dec       Impact factor: 5.864

5.  Effect of early corticosteroid therapy for Landau-Kleffner syndrome.

Authors:  P Lerman; T Lerman-Sagie; S Kivity
Journal:  Dev Med Child Neurol       Date:  1991-03       Impact factor: 5.449

6.  Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood.

Authors:  H Oguni; T Tanaka; K Hayashi; M Funatsuka; M Sakauchi; S Shirakawa; M Osawa
Journal:  Neuropediatrics       Date:  2002-06       Impact factor: 1.947

7.  A comparative study of hydrocortisone versus deflazacort in drug-resistant epilepsy of childhood.

Authors:  Salvatore Grosso; Mariangela Farnetani; Rosa Mostardini; Duccio Cordelli; Rosario Berardi; Paolo Balestri
Journal:  Epilepsy Res       Date:  2008-06-03       Impact factor: 3.045

8.  [Therapeutic trial with a fragment of ACTH (ACTH 4-10) in early childhood epilepsy (author's transl)].

Authors:  R P Willig; I Lagenstein
Journal:  Monatsschr Kinderheilkd       Date:  1980-02

9.  Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep.

Authors:  Marga Buzatu; Christine Bulteau; Cécilia Altuzarra; Olivier Dulac; Patrick Van Bogaert
Journal:  Epilepsia       Date:  2009-08       Impact factor: 5.864

Review 10.  Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.

Authors:  Craig Campbell; Pierre Jacob
Journal:  BMC Neurol       Date:  2003-09-08       Impact factor: 2.474

View more
  3 in total

Review 1.  Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies.

Authors:  Adam Strzelczyk; Susanne Schubert-Bast
Journal:  CNS Drugs       Date:  2021-01-21       Impact factor: 5.749

2.  Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort.

Authors:  Zachary M Grinspan; Kelly G Knupp; Anup D Patel; Elissa G Yozawitz; Courtney J Wusthoff; Elaine Wirrell; Ignacio Valencia; Nilika S Singhal; Douglas R Nordli; John R Mytinger; Wendy Mitchell; Cynthia G Keator; Tobias Loddenkemper; Shaun A Hussain; Chellamani Harini; William D Gaillard; Ivan S Fernandez; Jason Coryell; Catherine J Chu; Anne T Berg; Renee A Shellhaas
Journal:  Neurology       Date:  2021-07-15       Impact factor: 11.800

Review 3.  Microtubule Dynamics and Neuronal Excitability: Advances on Cytoskeletal Components Implicated in Epileptic Phenomena.

Authors:  Giuditta Gambino; Valerio Rizzo; Giuseppe Giglia; Giuseppe Ferraro; Pierangelo Sardo
Journal:  Cell Mol Neurobiol       Date:  2020-09-14       Impact factor: 5.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.